Sharon Cohen Vered

Sharon Cohen Vered is the current VP of CMC at NeuroSense Therapeutics. Sharon has over 25 years of experience in the pharmaceutical industry, with a focus on sterile dosage form development. Sharon started their career at Teva Pharmaceuticals in 1993, where they spent 15 years as Head of Sterile Dosage Form Development. In 2008, they joined Neuroderm as VP of CMC, and was with the company for 10 years. Sharon then spent a year at Orasis Pharmaceuticals as CMC before joining NeuroSense Therapeutics in January of 2018.

Sharon Cohen Vered has a PhD in biochemistry from Tel Aviv University, an M.Sc in biomedical engineering from the Technion - Israel Institute of Technology, and a B.Sc in chemical engineering from the Technion - Israel Institute of Technology.

Sharon Cohen Vered reports to Alon Ben-Noon, Co-Founder & CEO. Sharon Cohen Vered works with Oron Yacoby-Zeevi - Chief Scientific Officer, Avital Pushett - Head of ALS Clinical Program, and Niva Russek-Blum - VP, Discovery & IP Generator.